Guardian Pharmacy Services (NYSE:GRDN) Sets New 12-Month High After Better-Than-Expected Earnings

Key Points

• Guardian Pharmacy Services shares surged 12.3% to a new 52-week high of $45.80 after the company reported quarterly EPS of $0.29, beating estimates by $0.03, and revenue of $351.77 million versus expectations of $340.45 million.
• Analyst sentiment remains broadly positive, with seven Buy ratings and two Holds producing a “Moderate Buy” consensus and an average price target of $43.83, although some firms recently downgraded the stock to Hold.
• The company has a market capitalization of approximately $2.21 billion and trades at a price-to-earnings ratio of 53.78, while several institutional investors recently increased or initiated positions.

Guardian Pharmacy Services, Inc. (NYSE:GRDN - Get Free Report)'s share price reached a new 52-week high on Friday following a stronger than expected earnings report. The stock traded as high as $45.80 and last traded at $45.7110, with a volume of 43324 shares changing hands. The stock had previously closed at $39.47.

The company reported $0.29 EPS for the quarter, beating analysts' consensus estimates of $0.26 by $0.03. Guardian Pharmacy Services had a net margin of 3.64% and a return on equity of 30.72%. The company had revenue of $351.77 million for the quarter, compared to analyst estimates of $340.45 million.

Analyst Ratings Changes

Several equities analysts recently issued reports on GRDN shares. Wall Street Zen cut Guardian Pharmacy Services from a "buy" rating to a "hold" rating in a research report on Saturday, August 1st. Zacks Research downgraded Guardian Pharmacy Services from a "strong-buy" rating to a "hold" rating in a research note on Monday, May 11th. Truist Financial boosted their target price on Guardian Pharmacy Services from $43.00 to $47.00 and gave the company a "buy" rating in a report on Wednesday, June 17th. Weiss Ratings cut Guardian Pharmacy Services from a "hold (c+)" rating to a "hold (c)" rating in a research note on Monday, May 11th. Finally, Bank of America increased their price target on Guardian Pharmacy Services from $42.00 to $47.00 and gave the stock a "buy" rating in a report on Wednesday, June 17th. Seven research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company's stock. Based on data from MarketBeat, Guardian Pharmacy Services has an average rating of "Moderate Buy" and a consensus target price of $43.83.

Institutional Investors Weigh In On Guardian Pharmacy Services

Institutional investors have recently added to or reduced their stakes in the business. Ameritas Investment Partners Inc. boosted its stake in shares of Guardian Pharmacy Services by 26.5% in the third quarter. Ameritas Investment Partners Inc. now owns 1,647 shares of the company's stock valued at $43,000 after buying an additional 345 shares in the last quarter. Raymond James Financial Inc. purchased a new position in Guardian Pharmacy Services in the second quarter worth $43,000. State of Wyoming acquired a new stake in Guardian Pharmacy Services in the second quarter valued at $58,000. Strs Ohio acquired a new stake in Guardian Pharmacy Services in the fourth quarter valued at $75,000. Finally, Clearstead Advisors LLC boosted its position in shares of Guardian Pharmacy Services by 196.3% during the 4th quarter. Clearstead Advisors LLC now owns 2,628 shares of the company's stock worth $79,000 after purchasing an additional 1,741 shares in the last quarter.

Guardian Pharmacy Services Trading Up 12.3%

The firm has a market capitalization of $2.21 billion, a price-to-earnings ratio of 53.78, a PEG ratio of 2.73 and a beta of 0.10. The stock's 50 day moving average price is $40.84 and its two-hundred day moving average price is $37.05.

About Guardian Pharmacy Services

Guardian Pharmacy Services, Inc, a pharmacy service company, provides a suite of technology-enabled services designed to help residents of long-term health care facilities (LTCFs) in the United States. Its individualized clinical, drug dispensing, and administration capabilities are used to serve the needs of residents in lower acuity LTCFs, such as assisted living facilities and behavioral health facilities and group homes. The company's Guardian Compass includes dashboards created using data from its data warehouse to help its local pharmacies plan, track, and optimize their business operations; and GuardianShield Programs for LTCFs.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source